An observational study in Chlamydial Infections, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 14 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Sanofi · Observational
Among 79 studies in Chlamydia Infections with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Chlamydia Infections · United States.
Among the 79 studies in Chlamydia Infections with a site in United States, this one has the largest enrollment of the 22 observational ones, is one of 3 that started in 2025, is one of 22 observational ones, and was the 77th registered.
134 studies on the registry are indexed under Chlamydia Infections; 23 are open to participants now.
This study's enrollment of 4,878,935 is above the median of 402 across 31 observational studies indexed under Chlamydia Infections.
Browse Chlamydia Infections studies →8 of the 79 studies in Chlamydia Infections with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 14 Chlamydia Infections studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 14 Years to 44 Years · all sexes · no healthy volunteers.
The full table on the hub →79 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2025.
Median enrollment 511 across the 56 interventional studies, 373 across the 22 observational. Of the 67 that completed or were terminated, 21 (31%) have results posted.
12 of 79 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,557 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Chlamydia Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Chlamydia Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
Among the 79 studies in Chlamydia Infections with a site in United States, from their registry updates:
This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program.
There are two primary objectives for this study:
There are also two secondary objectives for this study:
For the primary objectives, the study population will include patients aged 14 to 44 years old identified between 1 January 2016 and 31 October 2024 in TriNetX USA Network. Patients are eligible if they have at least one ICD-10-CM diagnosis code for chlamydia or a known Nucleic Acid Amplification Test (NAAT) result.
For the secondary objectives, the study population includes 1.) patients aged 14 to 44 years with at least one ICD-10-CM diagnosis code for chlamydia between 1 February 2016 and 30 November 2023 in the MarketScan CCAE database and 2.) patients aged 14 to 44 years with an ICD-10-CM diagnosis code for chlamydia or a positive NAAT result for chlamydia between 1 January 2016 and 31 October 2024 in TriNetX Dataworks USA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria for Primary Objectives:
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Patients aged 14 to 44 years with an ICD-10-CM diagnosis of chlamydia documented in their EHR OR patients with a NAAT result for chlamydia (either positive or negative) during the study period (2016-2024) from the TriNetX USA Network
Patients aged 14 to 44 years with ≥1 ICD-10-CM diagnosis code for chlamydia between 2016 - 2023 in the MarketScan Commercial Claims and Encounters (CCAE) database
Patients aged 14 to 44 years with ≥1 ICD-10-CM diagnosis code for chlamydia or a positive NAAT result for chlamydia between 2016 -2024 in TriNetX Dataworks USA
Validity of ICD-10-CM Diagnostic Codes for Chlamydial Infections
Diagnostic performance of ICD-10-CM codes for chlamydial infections, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), compared to Nucleic Acid Amplification Test (NAAT) results for chlamydial infections
Time frame: From year 2016 through year 2024
Descriptive analyses of chlamydia patients
Describe demographic characteristics, laboratory testing, and treatment patterns among true positive and false negative chlamydia patients
Time frame: From year 2016 through year 2024
Validity of CCAE Database for Chlamydial Infections
Detect chlamydia cases using a mix of diagnostic codes, lab test codes, treatments, to detect/confirm chlamydia infection
Time frame: From year 2016 through year 2023
Comparison of chlamydia patient characteristics between EHR and claims RWD sources in the US
Compare demographics and clinical features (e.g., age, sex, treatment history, comorbidities) of chlamydia patients as seen in EHRs which contain clinical notes, lab results, and detailed medical histories and claims data
Time frame: From year 2016 through year 2024
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Sep 2026, 20 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.